Analytical Data
-
Gene name
MIP3b
- Application
-
Alternative Names
CCL19; CKb11; ELC; MIP3-B; SCYA19; Chemokine C-C-Motif Ligand 19; Beta Chemokine Exodus-3; CK Beta-11; EBI1-Ligand Chemokine; Small Inducible Cytokine Subfamily A19
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
D3ZI84
-
Expression Region
Asp32~Lys103
-
Molecular Weight
32kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MIP3b, also known as CCL19, is a chemokine that plays a crucial role in the immune system, primarily by guiding the migration of lymphocytes and other immune cells to sites of inflammation or lymphoid tissues. Its significance is underscored by its involvement in various physiological and pathological processes, including immune responses to infections, the regulation of immune cell trafficking, and the development of autoimmune diseases and cancers. Researchers have increasingly focused on MIP3b due to its potential therapeutic applications in modulating immune responses. Recombinant MIP3b protein is often produced for various studies, including its role in lymphocyte homing, the characterization of immune cell interactions, and the exploration of its signaling pathways. Understanding the precise mechanisms by which MIP3b influences immune cell behavior can provide valuable insights into designing novel immunotherapies and enhancing vaccine efficacy. Furthermore, the study of MIP3b's interactions with its receptors may lead to innovative strategies for targeting specific immune pathways in diseases characterized by immune dysregulation. Thus, the investigation of MIP3b and its recombinant forms remains a dynamic area of research, promising to unveil new therapeutic avenues for treating a range of immune-related conditions.
